Navigation Links
Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
Date:11/12/2008

PARSIPPANY, N.J., Nov. 12 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announces the promotion of William N. Garbarini, Jr. to Vice President of its new Orthopaedics and Urology Business Unit, recently formed by merging these clinical product areas. Garbarini was formerly Executive Director of Ferring's Orthopaedics Business Unit.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081112/NY45502 )

In his new role, Garbarini is responsible for Ferring's two marketed products in these areas, euflexxa(R) (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and PROSED(R) DS for the relief of discomfort of the lower urinary tract. He will also oversee the U.S. sales and marketing of Ferring's pipeline of urology products, including a GnRH antagonist for prostate cancer.

"Bill's exceptional talent, leadership and wealth of experience in pharmaceutical marketing have driven his rapid rise and recognition in the health care industry," said Wayne Anderson, President of Ferring. "After spearheading the growth of our infertility and orthopaedics businesses, he is extremely qualified to lead our new Orthopaedics and Urology unit."

During his tenure, Garbarini directed the launches of three key products in the Ferring portfolio. After joining Ferring in 2001 as a Product Director for its infertility franchise, he launched BRAVELLE(R), a highly purified, human-derived follicle-stimulating hormone (hFSH) for infertility treatment. Ferring quickly became a formidable player in the market and grew to become the leader in total infertility prescriptions.

Garbarini was soon promoted to the unit's Director of Marketing and oversaw the launch of MENOPUR(R) (menotropins for injection, USP), a purified human menopausal gonadotropin (hMG) for patients undergoing in vitro fertilization (IVF). The product grew Ferring's hMG segment and continued the Company's dominance in total infertility prescriptions.

In 2005, Garbarini became Senior Director of Marketing for Ferring's new Orthopaedic Business Unit, which further diversified Ferring's portfolio. He launched euflexxa(R) for the pain caused by knee osteoarthritis. Soon it became the fastest-growing product in Ferring's line. In 2006, he accepted further responsibility as the Executive Director of Sales and Marketing for the business unit.

Prior to joining Ferring, Garbarini was Director, Client Services for Caresoft, Inc. Previously, he served in various positions at Schering-Plough Corporation/Key Pharmaceuticals, Lowe McAdams Healthcare advertising agency, and Glaxo Wellcome, where he was honored as a top sales representative. Garbarini holds a B.S. degree in economics from the College of New Jersey and an M.B.A. degree in pharmaceutical management from Fairleigh Dickinson University, where he was granted membership in the Delta Mu Delta Honor Society.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R) (menotropins for injection, USP); REPRONEX(R) (menotropins for injection, USP); NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert for infertility. Ferring offers the Q?CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.

CONTACT: Tara Fisher

Kovak-Likly Communications

203-762-8833 or tfisher@KLCpr.com


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
2. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
3. Increase in Diagnostic Imaging Fueled by Self-Referring Doctors
4. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
5. Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: